Momenta Pharmaceuticals, Inc. (MNTA)

[floblu14]

JBOG: They reserved production space with GSK to produce the drug and are paying them $30 mil a year for the next couple of years to produce nothing.

AbbVie nets 7th Humira biosimilar deal, pushing Pfizer entry to 2023

In the seventh deal of its type, Pfizer has reached a license agreement with AbbVie, granting the pharma non-exclusive rights to sell its Humira biosimilar in the U.S. beginning in 2023 and resolving all litigation between the two companies.

Global sales of the drug rose by 9% year over year in the third quarter, despite the impact of four Humira biosimilars launching in Europe.

Settlement deals have come quickly for AbbVie, with the agreement with Pfizer following close on the heels of a deal with Momenta Pharmaceuticals which pushed a launch of that company's Humira (adalimumab) copy to November 2023.

Read more:
https://www.biopharmadive.com/news/abbvie-nets-7th-humira-biosimilar-deal-pushing-pfizer-entry-to-2023/543459/